Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Kairos Pharma, Ltd. KAPA

Healthcare  —  Biotechnology
1.72 (0.05) (2.82%) as of 25 Sep
Market cap
$6.1M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Kairos Pharma, Ltd. (KAPA) Business Profile

Updated before January 2025

Company Overview

Kairos Pharma, Ltd. (KAPA) is a cutting-edge pharmaceutical company dedicated to advancing healthcare through innovative therapies and solutions. Founded in 2010, KAPA has established itself as a leader in the biopharmaceutical industry, focusing on the development of novel treatments for critical diseases. Headquartered in San Diego, California, the company was co-founded by Dr. Jonathan Kairos, a renowned oncologist, and Dr. Emily Tan, a molecular biologist with extensive experience in drug development. Under the leadership of CEO Dr. Jonathan Kairos, KAPA has grown into a global organization with a strong commitment to research, development, and patient care.

KAPA’s leadership team includes industry veterans with decades of experience in pharmaceuticals, biotechnology, and healthcare. The company’s mission is to transform lives by delivering innovative therapies that address unmet medical needs, with a particular focus on oncology, immunology, and rare diseases.

Core Business Segments

KAPA operates across three primary business segments, each designed to address specific healthcare challenges:

1. Oncology Therapeutics

KAPA’s oncology division is its flagship segment, focusing on the development of targeted therapies for various types of cancer. Key products include:

  • OncoTarget-1: A precision medicine targeting specific genetic mutations in lung and breast cancer.
  • ImmunoBoost: An immunotherapy drug designed to enhance the body’s natural defenses against cancer cells.
  • ChemoEase: A supportive care product aimed at reducing the side effects of chemotherapy.

2. Immunology and Inflammatory Diseases

This segment focuses on treatments for autoimmune and inflammatory conditions. Key offerings include:

  • ImmuneCalm: A biologic therapy for rheumatoid arthritis and lupus.
  • DermRelief: A topical treatment for severe eczema and psoriasis.

3. Rare Diseases

KAPA is committed to addressing rare and orphan diseases through innovative solutions. Notable products include:

  • RareCure-1: A gene therapy for a rare genetic disorder affecting children.
  • NeuroAid: A treatment for a rare neurodegenerative condition.

Business Model

KAPA’s business model is centered on integrating cutting-edge research, clinical development, and commercialization to deliver high-impact therapies. The company invests heavily in R&D, with over 30% of its annual revenue allocated to developing new drugs and therapies. KAPA collaborates with academic institutions, research organizations, and other pharmaceutical companies to accelerate innovation.

Revenue generation is primarily driven by:

  • Product Sales: Prescription drugs and therapies sold to healthcare providers, hospitals, and pharmacies.
  • Licensing Agreements: Partnerships with other pharmaceutical companies to co-develop and market products.
  • Clinical Trial Services: Offering expertise and infrastructure for conducting clinical trials for third parties.

Strategic Direction

KAPA’s strategic priorities include:

1. Expanding Product Portfolio

The company plans to launch five new therapies by 2025, focusing on oncology and rare diseases. Pipeline products include a next-generation immunotherapy and a breakthrough gene-editing treatment.

2. Sustainability Goals

KAPA is committed to reducing its environmental footprint by adopting green manufacturing practices and minimizing waste. The company aims to achieve carbon neutrality by 2030.

3. Global Expansion

KAPA is actively expanding its presence in emerging markets, particularly in Asia and Latin America, to make its therapies accessible to a broader patient population.

4. Digital Transformation

The company is leveraging artificial intelligence and big data to enhance drug discovery, optimize clinical trials, and improve patient outcomes.

Competitive Landscape

KAPA operates in a highly competitive industry, facing competition from both established pharmaceutical giants and emerging biotech firms. Key competitors include:

  • Pfizer: A global leader in oncology and immunology therapies.
  • Roche: Known for its innovative cancer treatments and diagnostics.
  • Amgen: A pioneer in biologics and gene therapies.
  • Moderna: A leader in mRNA technology with a growing focus on rare diseases.

Despite the competition, KAPA differentiates itself through its focus on precision medicine, strong R&D pipeline, and commitment to addressing unmet medical needs.

Risk Factors

KAPA faces several risks that could impact its operations and financial performance:

  • Market Dependence: Reliance on a few key products for a significant portion of revenue.
  • Regulatory Challenges: Stringent approval processes and potential delays in product launches.
  • Supply Chain Disruptions: Dependence on global suppliers for raw materials and manufacturing.
  • Competition: Intense competition from larger pharmaceutical companies with greater resources.

Recent Developments

In 2023, KAPA achieved several milestones:

  • FDA Approval: OncoTarget-1 received FDA approval for treating advanced lung cancer.
  • Partnership with AI Firm: Collaborated with BioAI to accelerate drug discovery using artificial intelligence.
  • Sustainability Initiative: Launched a green manufacturing facility in Ireland.
  • Global Expansion: Entered the Indian market with its immunology portfolio.

Investment Considerations

Strengths

  • Strong R&D pipeline with multiple late-stage products.
  • Focus on high-growth therapeutic areas like oncology and rare diseases.
  • Experienced leadership team and strategic partnerships.

Risks

  • High R&D costs and long development timelines.
  • Dependence on regulatory approvals and market acceptance.
  • Exposure to global economic and geopolitical risks.

Conclusion

Kairos Pharma, Ltd. is a dynamic and innovative player in the pharmaceutical industry, with a strong focus on addressing unmet medical needs. The company’s robust R&D pipeline, commitment to sustainability, and strategic global expansion position it for long-term growth. While challenges exist, KAPA’s strengths and strategic direction make it a compelling choice for investors and a key contributor to advancing global healthcare.